Ostomy Care
Continence Care
Wound & Skin Care
Interventional Urology

Modern Slavery Statement - Financial Year Ending 30 September 2026

04 November 2026

Coloplast Pty Ltd.
Level 7, 1 Peters Avenue
Mulgrave
Victoria 3170
Australia
Tel: +61 3 9541 1111
www.coloplast.com.au
A.C.N. 054 949 692
A.B.N. 57 054 949 692

This statement is made by Coloplast Pty Ltd under the Modern Slavery Act 2018 (Cth) in respect of the financial year ending 30 September 2026.

COLOPLAST PTY LTD ACN 054 949 692, with its registered address at LEVEL 7, 1 PETERS AVENUE, MULGRAVE VIC 3170, is an **Australian subsidiary** of Coloplast A/S, whose registered address is Holtedam 1-3, DK3050 Humlebæk, Denmark. In this statement, references to "Coloplast Australia" mean the Australian reporting entity, while references to the "Coloplast Group" mean Coloplast A/S and its subsidiaries.

Structure, operations and supply chain:

Coloplast develops and markets products and services that make life easier for people with intimate healthcare conditions within Ostomy Care, Continence Care, Wound & Tissue Repair, Voice & Respiratory Care and Interventional Urology.

In Australia, Coloplast Australia markets and supplies Coloplast products to hospitals, healthcare providers, distributors and other customers. Coloplast Australia's operations are primarily sales, marketing, distribution and related support functions, and employs approximately 155 staff. The products supplied in Australia are principally manufactured and sourced through the Coloplast Group's global operations and supply chain and are sold under the Coloplast and Atos brands.

The Coloplast Group operates globally, with sales subsidiaries in more than 40 countries. There are production sites in Denmark, Hungary, the United States, China, France, Sweden, Germany, Costa Rica, Portugal and Iceland.

Policy:

As stated in our Code of Conduct 'Coloplast BEST'. Coloplast supports, respects and protects internationally recognised human rights, including labour rights as made operational with the United Nations Guiding Principles on Business & Human Rights and as framed in the United Nations Global Compact, of which Coloplast has been a signatory since 2002.

Our commitment to human rights, which covers areas such as forced labour, slavery, child labour, sex trafficking, workplace abuse and human trafficking, is outlined in our Human Rights Policy, available on Coloplast.com.

Coloplast expects employees to avoid and mitigate all negative human rights impacts and to inform, through our management system or grievance mechanisms, any breach of this expectation or doubts that our expectations are being met. Grievances can be raised via the Ethics Hotline, available for anyone wishing to raise a grievance.

Coloplast expects its business partners and all other strategic partners to understand and address our expectations related to human rights within their value chain and to inform

04 November 2026

Coloplast Pty Ltd.
Level 7, 1 Peters Avenue
Mulgrave
Victoria 3170
Australia
Tel: +61 3 9541 1111
www.coloplast.com.au
A.C.N. 054 949 692
A.B.N. 57 054 949 692

employees of Coloplast or through Coloplast's grievance mechanism if expectations are not being met.

Modern slavery risks in our operations and supply chains:
Coloplast Australia's direct operations primarily comprise sales, marketing, distribution and related support functions. Given the nature of these activities and the professional skills required, the risk of modern slavery in its direct operations is considered comparatively low. Potential risks are more likely to arise in the broader supply chain, particularly in connection with the manufacture and sourcing of products, raw materials and services, and where activities involve vulnerable workers, labour intermediaries, higher-risk jurisdictions or limited supply-chain visibility. Coloplast Australia addresses these risks through the Coloplast Group's supplier due diligence, screening, audit and corrective-action processes described below.

Actions taken to assess and address modern slavery risks:
As part of its evaluation of suppliers, Coloplast actively conducts due diligence and audits of existing raw materials suppliers and screen new suppliers for compliance within human rights and labour rights. For other suppliers, Coloplast has implemented a human rights and compliance due diligence process for both selected existing and new suppliers in some countries and is now working to extend the process across the organisation.

Coloplast follows up on findings from due diligence process, audit and screening to ensure necessary improvements are made or, where appropriate, corrective action plans are implemented. Depending on the nature of the findings, Coloplast aims to co-operate with suppliers to improve conditions provided that the suppliers show a genuine interest and willingness to comply with Coloplast's standards and expectations. Coloplast will terminate the relationship if it identifies any (i) zero tolerance issues, (ii) issues that cause a negative effect on Coloplast permanent and/or temporary employees, Coloplast contractors, suppliers and/or services providers, Coloplast supply chain workers, customer or affected communities, or (iii) if suppliers are not willing to change needed improve areas

Audits:
Coloplast's supplier audit programme focuses on high-risk countries. All raw material suppliers in high-risk countries are evaluated as part of the approval process and a reassessment is completed every third year thereafter.

Training:
Coloplast provides training for new and existing employees on its Code of Conduct as well as other policies. Coloplast continues to mitigate the risks around Supply and Distribution, and for this purpose Coloplast has a Supplier and a Distributor portal, respectively, which includes the required training on the Codes of Conduct and expected standards.

Assessing effectiveness:

04 November 2026

Coloplast Pty Ltd.
Level 7, 1 Peters Avenue
Mulgrave
Victoria 3170
Australia
Tel: +61 3 9541 1111
www.coloplast.com.au
A.C.N. 054 949 692
A.B.N. 57 054 949 692

Coloplast Australia assesses the effectiveness of its actions by considering the outcomes of the Coloplast Group's supplier due diligence, screening and audit processes, follow-up on findings and corrective actions, relevant training and grievance mechanisms. These processes support the ongoing review and improvement of measures to identify and address modern slavery risks.
The Coloplast Group also reports annually on any human or labour rights issues, and disclose any mitigating actions in the integrated Annual Report.
Coloplast is a member of the Pharmaceutical Supply Chain Initiative (PSCI), to strengthen and improve the responsible value chain practices with shared learnings from this group.

Consultation:
In preparing this statement, Coloplast Australia consulted with relevant functions within the Coloplast Group involved in legal and compliance, human rights, procurement and supply-chain management. This consultation informed the description of Coloplast Australia's operations, modern slavery risks, and the actions taken to assess and address those risks. For the purposes of the consultation criterion, Coloplast Australia has considered the entities that it owns or controls. This statement is subject to approval by the Board of Directors of Coloplast Australia and signature by a director on its behalf.



Kris Hollund
Vice President ANZ and board chair
(on behalf of the Coloplast Australia Pty Ltd board of directors)